The molecular characterization and therapeutic strategies of papillary renal cell carcinoma

Qiwei Chen, Liang Cheng, Quanlin Li

Research output: Contribution to journalReview article

Abstract

Introduction: Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behavior. In this review, we summarize the current progression on pRCC in molecular level. Our findings highlight the need for molecular markers to accurately subtype pRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Areas covered: This review highlights the need for molecular markers to accurately subtype PRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Expert commentary: There are mainly two subtypes of pRCC based on histology. However, little is known about the genetic characterization of the sporadic forms of pRCC and there are currently no standard forms of therapy for patients with advanced disease. Both MET inhibitors and immunotherapy may be effective in advanced pRCC treatment. Therefore, understanding the molecular basis of pRCC and identifying the main goal of treatment is crucial for the selection of the best strategy.

Original languageEnglish (US)
Pages (from-to)169-175
Number of pages7
JournalExpert Review of Anticancer Therapy
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Renal Cell Carcinoma
Proxy
Therapeutics
Clinical Trials
Kidney Neoplasms
Immunotherapy
Histology

Keywords

  • genetic
  • mutation
  • Papillary renal cell carcinoma
  • survival prognosis
  • the cancer genome atlas

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

The molecular characterization and therapeutic strategies of papillary renal cell carcinoma. / Chen, Qiwei; Cheng, Liang; Li, Quanlin.

In: Expert Review of Anticancer Therapy, Vol. 19, No. 2, 01.02.2019, p. 169-175.

Research output: Contribution to journalReview article

@article{e73f98b32935418bb1219a17022aaa08,
title = "The molecular characterization and therapeutic strategies of papillary renal cell carcinoma",
abstract = "Introduction: Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behavior. In this review, we summarize the current progression on pRCC in molecular level. Our findings highlight the need for molecular markers to accurately subtype pRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Areas covered: This review highlights the need for molecular markers to accurately subtype PRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Expert commentary: There are mainly two subtypes of pRCC based on histology. However, little is known about the genetic characterization of the sporadic forms of pRCC and there are currently no standard forms of therapy for patients with advanced disease. Both MET inhibitors and immunotherapy may be effective in advanced pRCC treatment. Therefore, understanding the molecular basis of pRCC and identifying the main goal of treatment is crucial for the selection of the best strategy.",
keywords = "genetic, mutation, Papillary renal cell carcinoma, survival prognosis, the cancer genome atlas",
author = "Qiwei Chen and Liang Cheng and Quanlin Li",
year = "2019",
month = "2",
day = "1",
doi = "10.1080/14737140.2019.1548939",
language = "English (US)",
volume = "19",
pages = "169--175",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - The molecular characterization and therapeutic strategies of papillary renal cell carcinoma

AU - Chen, Qiwei

AU - Cheng, Liang

AU - Li, Quanlin

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behavior. In this review, we summarize the current progression on pRCC in molecular level. Our findings highlight the need for molecular markers to accurately subtype pRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Areas covered: This review highlights the need for molecular markers to accurately subtype PRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Expert commentary: There are mainly two subtypes of pRCC based on histology. However, little is known about the genetic characterization of the sporadic forms of pRCC and there are currently no standard forms of therapy for patients with advanced disease. Both MET inhibitors and immunotherapy may be effective in advanced pRCC treatment. Therefore, understanding the molecular basis of pRCC and identifying the main goal of treatment is crucial for the selection of the best strategy.

AB - Introduction: Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behavior. In this review, we summarize the current progression on pRCC in molecular level. Our findings highlight the need for molecular markers to accurately subtype pRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Areas covered: This review highlights the need for molecular markers to accurately subtype PRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Expert commentary: There are mainly two subtypes of pRCC based on histology. However, little is known about the genetic characterization of the sporadic forms of pRCC and there are currently no standard forms of therapy for patients with advanced disease. Both MET inhibitors and immunotherapy may be effective in advanced pRCC treatment. Therefore, understanding the molecular basis of pRCC and identifying the main goal of treatment is crucial for the selection of the best strategy.

KW - genetic

KW - mutation

KW - Papillary renal cell carcinoma

KW - survival prognosis

KW - the cancer genome atlas

UR - http://www.scopus.com/inward/record.url?scp=85060191503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060191503&partnerID=8YFLogxK

U2 - 10.1080/14737140.2019.1548939

DO - 10.1080/14737140.2019.1548939

M3 - Review article

VL - 19

SP - 169

EP - 175

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 2

ER -